Ventilator-associated pneumonia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 21: | Line 21: | ||
==Treatment== | ==Treatment== | ||
[[Ventilator-associated pneumonia clinical strategy| | [[Ventilator-associated pneumonia clinical strategy|Clinical Strategy]] | [[Ventilator-associated pneumonia medical therapy|Medical Therapy]] | [[Ventilator-associated pneumonia prevention|Prevention]] | [[Ventilator-associated pneumonia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Ventilator-associated pneumonia future or investigational therapies|Future or Investigational Therapies]] | ||
== Case Studies == | == Case Studies == | ||
Revision as of 17:23, 25 March 2013
Template:Ventilator-associated pneumonia For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]
Synonyms and keywords: VAP
Overview
Definition
Historical Perspective
Pathophysiology
Causes
Differentiating Ventilator-Associated Pneumonia from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | Other Imaging Findings | Other Diagnostic Studies
Treatment
Clinical Strategy | Medical Therapy | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies